Nowell P C
Ann Clin Lab Sci. 1974 Jul-Aug;4(4):234-40.
Chromosome studies may be of value in determining the diagnosis or prognosis in leukemia and related states. They are rarely helpful with solid neoplasms. Special technical problems associated with such investigations in tumor material must be appreciated. In cases where the diagnosis of acute leukemia is in doubt, demonstration of a chromosome change in the immature cells of blood or marrow is strong evidence of neoplasia; however, the absence of a cytogenetic abnormality does not rule out the diagnosis. The Philadelphia chromosome (Ph) is present in nearly every typical case of chronic granulocytic leukemia (CGL) and may confirm the diagnosis. Absence of the Ph chromosome in CGL or the appearance of additional cytogenetic changes in the neoplastic cells are indications of a poor prognosis. In "preleukemic" myeloproliferative disorders (except polycythemia vera) or unexplained pancytopenia, a clone of chromosomally abnormal marrow cells commonly indicates that clinical leukemia will soon become manifest; conversely, normal marrow chromosomes in these states are often correlated with a prolonged indolent course.
染色体研究对于确定白血病及相关病症的诊断或预后可能具有价值。它们对实体瘤很少有帮助。必须认识到与肿瘤材料此类研究相关的特殊技术问题。在急性白血病诊断存疑的病例中,血液或骨髓未成熟细胞中染色体变化的证明是肿瘤形成的有力证据;然而,细胞遗传学异常的缺失并不能排除诊断。费城染色体(Ph)几乎存在于每一例典型的慢性粒细胞白血病(CGL)病例中,可确诊该病。CGL中缺失Ph染色体或肿瘤细胞中出现其他细胞遗传学变化提示预后不良。在“白血病前期”骨髓增殖性疾病(真性红细胞增多症除外)或不明原因的全血细胞减少症中,一群染色体异常的骨髓细胞通常表明临床白血病即将显现;相反,这些状态下正常的骨髓染色体常与病程延长且进展缓慢相关。